208944-55-2 Usage
Description
METHYL 3-AMINO-5-(4-ISOBUTYLPHENYL)THIOPHENE-2-CARBOXYLATE is a complex chemical compound that is a thiophene derivative. It features an amino group and an ester group, with the addition of an isobutylphenyl group contributing to its intricate molecular structure. METHYL 3-AMINO-5-(4-ISOBUTYLPHENYL)THIOPHENE-2-CARBOXYLATE may hold potential for applications in the pharmaceutical or chemical industries, but further research and testing are required to ascertain its specific uses and properties.
Uses
Used in Pharmaceutical Industry:
METHYL 3-AMINO-5-(4-ISOBUTYLPHENYL)THIOPHENE-2-CARBOXYLATE is used as a chemical intermediate for the development of new pharmaceutical compounds, given its unique structure that may offer novel therapeutic properties.
Used in Chemical Industry:
In the chemical industry, METHYL 3-AMINO-5-(4-ISOBUTYLPHENYL)THIOPHENE-2-CARBOXYLATE may serve as a building block or reactant in the synthesis of various complex organic molecules, potentially leading to advancements in material science or the creation of new chemical products.
Check Digit Verification of cas no
The CAS Registry Mumber 208944-55-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,8,9,4 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 208944-55:
(8*2)+(7*0)+(6*8)+(5*9)+(4*4)+(3*4)+(2*5)+(1*5)=152
152 % 10 = 2
So 208944-55-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H19NO2S/c1-10(2)8-11-4-6-12(7-5-11)14-9-13(17)15(20-14)16(18)19-3/h4-7,9-10H,8,17H2,1-3H3
208944-55-2Relevant articles and documents
Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1
Tavares, Francis X.,Al-Barazanji, Kamal A.,Bigham, Eric C.,Bishop, Michael J.,Britt, Christy S.,Carlton, David L.,Feldman, Paul L.,Goetz, Aaron S.,Grizzle, Mary K.,Guo, Yu C.,Handlon, Anthony L.,Hertzog, Donald L.,Ignar, Diane M.,Lang, Daniel G.,Ott, Ronda J.,Peat, Andrew J.,Zhou, Hui-Qiang
, p. 7095 - 7107 (2008/04/18)
The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pKas and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.